92 related articles for article (PubMed ID: 1449475)
1. Dual role of S-nitrosocaptopril as an inhibitor of angiotensin-converting enzyme and a nitroso group carrier.
Park JW
Biochem Biophys Res Commun; 1992 Nov; 189(1):206-10. PubMed ID: 1449475
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic effects of S-nitrosocaptopril crystals as a nitric oxide donor.
Jia L; Wu CC; Guo W; Young X
Eur J Pharmacol; 2000 Mar; 391(1-2):137-44. PubMed ID: 10720645
[TBL] [Abstract][Full Text] [Related]
3. The effects of S-nitrosocaptopril on renal filtration and blood pressure in rats.
Jia L; Blantz RC
Eur J Pharmacol; 1998 Jul; 354(1):33-41. PubMed ID: 9726628
[TBL] [Abstract][Full Text] [Related]
4. [A design of a novel compound S-nitrosocaptopril possessing the capacities of both angiotensin converting enzyme inhibitors and NO donors].
Jia L
Sheng Li Ke Xue Jin Zhan; 1999 Jan; 30(1):53-6. PubMed ID: 12532851
[No Abstract] [Full Text] [Related]
5. S-nitrosocaptopril. I. Molecular characterization and effects on the vasculature and on platelets.
Loscalzo J; Smick D; Andon N; Cooke J
J Pharmacol Exp Ther; 1989 Jun; 249(3):726-9. PubMed ID: 2659776
[TBL] [Abstract][Full Text] [Related]
6. Captopril and S-nitrosocaptopril as potent radiosensitizers: Comparative study and underlying mechanisms.
Jordan BF; Peeterbroeck J; Karroum O; Diepart C; Magat J; Grégoire V; Gallez B
Cancer Lett; 2010 Jul; 293(2):213-9. PubMed ID: 20144849
[TBL] [Abstract][Full Text] [Related]
7. S-nitrosocaptopril. II. Effects on vascular reactivity.
Cooke JP; Andon N; Loscalzo J
J Pharmacol Exp Ther; 1989 Jun; 249(3):730-4. PubMed ID: 2659777
[TBL] [Abstract][Full Text] [Related]
8. S-nitrosocaptopril formation in aqueous acid and basic medium. A vasodilator and angiotensin converting enzyme inhibitor.
Sexto A; Iglesias E
Org Biomol Chem; 2011 Oct; 9(20):7207-16. PubMed ID: 21860877
[TBL] [Abstract][Full Text] [Related]
9. The hemodynamic effects of S-nitrosocaptopril in anesthetized dogs.
Shaffer JE; Lee F; Thomson S; Han BJ; Cooke JP; Loscalzo J
J Pharmacol Exp Ther; 1991 Feb; 256(2):704-9. PubMed ID: 1899703
[TBL] [Abstract][Full Text] [Related]
10. Optimization of S-Nitrosocaptopril Monohydrate Storage Conditions Based on Response Surface Method.
Huang L; Zhou Y; Wang Y; Lin M
Molecules; 2021 Dec; 26(24):. PubMed ID: 34946614
[TBL] [Abstract][Full Text] [Related]
11. S-nitrosocaptopril: in vitro characterization of pulmonary vascular effects in rats.
Tsui DY; Gambino A; Wanstall JC
Br J Pharmacol; 2003 Mar; 138(5):855-64. PubMed ID: 12642387
[TBL] [Abstract][Full Text] [Related]
12. [Angiotensin-converting enzyme inhibitors as neutralizers of hydroxyl radical].
Mira ML; Silva MM; Queirós MJ; Manso C
Rev Port Cardiol; 1992 May; 11(5):425-30. PubMed ID: 1325814
[TBL] [Abstract][Full Text] [Related]
13. Interaction of gold nanoparticles mediated by captopril and S-nitrosocaptopril: the effect of manganese ions in mild acid medium.
Iglesias E; Prado-Gotor R
Phys Chem Chem Phys; 2015 Jan; 17(1):644-54. PubMed ID: 25407561
[TBL] [Abstract][Full Text] [Related]
14. The role of the thiol group in the antithrombotic action of captopril.
Pawlak R; Chabielska E; Matys T; Kucharewicz I; Buczko W
Thromb Haemost; 2000 Nov; 84(5):919-20. PubMed ID: 11127878
[No Abstract] [Full Text] [Related]
15. Structural relationships of angiotensin converting-enzyme inhibitors to pharmacologic activity.
Ondetti MA
Circulation; 1988 Jun; 77(6 Pt 2):I74-8. PubMed ID: 2836111
[TBL] [Abstract][Full Text] [Related]
16. [Synthesis of angiotensin converting enzyme inhibitor, captopril ester derivatives].
Wu M; Xie MH; Zhao DY; Chen GY; Wang YC; Kong H
Yao Xue Xue Bao; 1988; 23(12):890-4. PubMed ID: 3076736
[No Abstract] [Full Text] [Related]
17. The molecular basis for the selection of captopril cis and trans conformations by angiotensin I converting enzyme.
Tzakos AG; Naqvi N; Comporozos K; Pierattelli R; Theodorou V; Husain A; Gerothanassis IP
Bioorg Med Chem Lett; 2006 Oct; 16(19):5084-7. PubMed ID: 16889963
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and antienzymic activity of two new angiotensin converting enzyme inhibitors.
Dudkiewicz J; Suska T; Tautt J; Paruszewski R
Pol J Pharmacol Pharm; 1991; 43(1):33-8. PubMed ID: 1663247
[TBL] [Abstract][Full Text] [Related]
19. [From teprotide to captopril. Rational design of ACE inhibitors].
Nemec K; Schubert-Zsilavecz M
Pharm Unserer Zeit; 2003; 32(1):11-6. PubMed ID: 12577755
[No Abstract] [Full Text] [Related]
20. Differential influences of angiotensin converting-enzyme inhibitors on the coronary circulation.
van Gilst WH; Scholtens E; de Graeff PA; de Langen CD; Wesseling H
Circulation; 1988 Jun; 77(6 Pt 2):I24-9. PubMed ID: 3286044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
